Based on 2022 data, it is estimated that among the ~ 2 million people diagnosed with non-small cell lung cancer (NSCLC) globally, about 60,000 have an activating HER2 mutation.1-3 Activating HER2 mutations NSCLC were identified in 2004.4 But, despite ongoing research, there’s still much to learn two decades later.1,4-6
It’s time to build a clearer picture
When you know who’s at risk and the impact this diagnosis can have, you help us step closer to understanding the complexities of this devastating disease.
Who’s affected?
While activating HER2 mutations are rare, anyone with advanced NSCLC could have a HER2 driver mutation.3,4 And, for the 2-4% of patients who do have it,3,4 time is of the essence.
That’s why it’s so vital we keep driving research forward.
What does this diagnosis mean?
Sadly, patients with these mutations may experience a worse prognosis than those with other driver mutations.7,8 More than 40% of people with HER2-mutant advanced NSCLC experience brain metastasis,9 which may significantly impact their life.
Despite this additional burden, we still don't fully understand the complexities of this diagnosis.3-6 That's why we're pushing for more momentum, through research and our dedication to the people most affected by this disease – your patients.
NGS testing brings clarity
Activating HER2 mutations and overexpression are two distinct disease alterations in NSCLC.10 Next-generation sequencing (NGS) testing is a comprehensive way to identify activating HER2 mutations. Immunohistochemistry (IHC), on the other hand, is used to detect HER2 overexpression.10,11
Being able to accurately identify HER2-mutant advanced NSCLC is crucial as it can help you determine the best next steps for each patient.10,11
Ultimately, an NGS test is always important to consider for people with advanced NSCLC.10-12
We need your momentum
HER2-mutant advanced NSCLC was identified in 2004.4 But there’s still much to learn.2-6
While we’re investing in research to better understand the complexities of this disease, you can help make a real difference for your patients by:
- Raising awareness about HER2-mutant advanced NSCLC and its burden
- Being a proactive NGS tester for all your patients with advanced NSCLC
- Staying up to date with the latest innovations and clinical trial findings
Let’s keep pushing for more momentum in HER2-mutant advanced NSCLC, together.
Sources:
Bray F, et al. CA Cancer J Clin. 2024;74(3)229-263.
Sharma R. Int J Clin Oncol. 2022;27(4):665-675.
Yu X et al. Front Oncol. 2022;12-860313.
Stephens P, et al. Nature. 2004;431(7008):525-526.
Mitchell CL, et al. Diagnostics (Basel). 2023;13(6):1117.
Uy NF, et al. Cancers (Basel). 2022;14(17):4155.
Wang Y, et al. BMC Cancer. 2018;18(1):326.
Yang S, et al. Transl Lung Cancer Res. 2021;10(2):753-765.
Offin M, et al. Cancer. 2019;125(24):4380-4387.
IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer. International Association for the Study of Lung Cancer. February 2023.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-Small Cell Lung Cancer. Version 4. 2025 – May 23, 2025.
Kerr KM, et al. Lung Cancer. 2021;154-161-175.
